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Genetic changes through allelic loss and nucleic acid or protein modiﬁcations are the main contrib-
utors to loss of function of tumor suppressor proteins. In particular, epigenetic silencing of genes by
promoter hypermethylation is associated with increased tumor severity and poor survival. The
RASSF (Ras association domain family) family of proteins consists of 10 members, many of which
are tumor suppressor proteins that undergo loss of expression through promoter methylation in
numerous types of cancers such as leukemia, melanoma, breast, prostate, neck, lung, brain, colorec-
tal and kidney cancers. In addition to their tumor suppressor function, RASSF proteins act as scaf-
folding agents in microtubule stability, regulate mitotic cell division, modulate apoptosis, control
cell migration and cell adhesion, and modulate NFjB activity and the duration of inﬂammation.
The ubiquitous functions of these proteins highlight their importance in numerous physiological
pathways. In this review, we will focus on the biological roles of the RASSF family members and their
regulation.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The RASSF family of proteins is comprised of ten members each
with multiple splice variants, with the exception of RASSF9 and 10
[1,2]. These proteins were named due to the presence of a Ras asso-
ciation (RA) domain in their N-terminus or C-terminus. The RA do-
main potentially interacts with the Ras GTPase family of proteins
[2] that control a number of cellular processes including mem-
brane trafﬁcking, apoptosis, and proliferation [1–5]. Direct associ-
ation with K-Ras has been only observed for RASSF2, 4, 5A, 6 and
9 [6–8]. In addition, RASSF proteins have several other functional
domains that modulate associations with other proteins (see
Table 1 for the list of RASSF interacting partners). These include a
Salvador-RASSF-Hippo (SARAH) domain involved in several pro-
tein–protein interactions and for homo- and heterodimerization
of RASSF isoforms. RASSFs can associate via the SARAH domain
with downstream kinases such as mammalian sterile 20-like
kinases (MST1 and MST2 [mammalian Hippo] also known as orSTK4 and STK3 respectively) and the mammalian orthologue of
the tumor suppressor Salvador, SAV1 in order to promote apopto-
sis [9]. These various structural domains allow for associations
with numerous molecules and determine RASSF proteins’ involve-
ment in several biological pathways in order to carry out tumor
suppressor functions.
An ATM phosphorylation site is present on some RASSF proteins
(RASSF1A and RASSF1C), and RASSF1A and RASSF1C also contain an
N-terminal protein kinase C conserved region 1 (C1) domain that
co-localizes with microtubules [1]. The C1 domain has also been
demonstrated to allow for the association of RASSF1A with death
receptor complexes, such as TNF-R1 and TRAIL [10]. The ATM
phosphorylation site has been found to be phosphorylated in sev-
eral RASSF proteins upon DNA damage/repair [11] (Reviewed in
[12]).
2. The diverse nature and biological function of RASSF proteins
2.1. RASSF1A
In 2000 Dammann et al. cloned a gene that was mapped to the
3p21.3 region, whose genomic instability was frequently described
in lung cancer. The gene was named RASSF1 as it contains Ras-
association domain [13]. RASSF1 has eight transcripts (A–H),
Table 1
Summary of currently known biological information of the RASSF family of proteins.
RASSF isoform Chromosome/MW Biological functions Interacting proteins Mice knockout
1A 3p21
39.2 kDa
Regulates:
 MST kinase-dependent apoptosis [42,44,109]
 Death-receptor dependent apoptosis
[40,41,175]
 Microtubule formation and stabilization
[14,176]
 Cell cycle [35,165,176]
 Mitosis [25]
 Stability of mitotic cyclins and the timing of
mitotic progression by inhibiting APC-Cdc20
[27,28,31]
 Cardiac hypertrophy [49]Modulates NFjB activ-
ity [46,50]
Inhibits b-catenin accumulation [5]
Involved in DNA repair [12]
Stabilizes p53 [36] and p73 [11,45]
Protects from inﬂammation-induced injury [46]
MST1 [42–
44,50,168,177]
MST2 [45,177]
MOAP1 [40,41,175]
14–3-3 [109]
RABP1 [25]
Cdc20 [28]
Aurora A/B
[29,165,169]
MAP1B, MAP1S [14]
MDM2 [36]
Ran [176]
Rap1A [178]
RASS1A, RASSF5A [81]
p120 E4F [33]
Chk1 [170]
DDB1[172]
H-Ras [179]
ATM [11]
Skp2 [166]
Yes [47,48].
Spontaneous tumorigenesis [47];
susceptible to DSS-induced colitis
[46]
1C 3p21
31.2 kDa
Stimulates cell growth, may promote metastasis
and survival of cancer cells [16]
Promotes cell migration, attenuates apoptosis [17]
Silencing resulted in a decrease in osteosarcoma
and lung cancer cell proliferation [16,18]
Inhibits b-catenin degradation [5]
Activates SAPK/JNK signaling pathway [54]
Down-regulated by CAS/CS1L [180]
MST1 [43,177]
MST2 [177]
IGFBP5 [18]
TFPI-2 [56]
bTrCP [5]
DAXX [54,55]
No
2 20p13
37.8 kDa
Inhibits cell growth, arrests cell cycle [58,62]
Involved in actin cytoskeleton organization [148]
Induces apoptosis [58,62,145]
Suppresses transcriptional activity of NFjB [181]
Inhibits MST2 activity [93]
K-Ras [62]
PAR4 [64]
MST1 [66,177]
MST2 [177]
Yes [67]
growth retardation, systematic
haematopoietic anomalies, defects in
osteoclast and osteoblast
differentiation
3 12q14.1
28.6 kDa
Regulates apoptosis and cell cycle via p53
stabilization, possibly involved in DNA repair
[69,72]
MOAP1, Mdm2 [72]
MST1, MST2 [72,177]
Not available
4 10q11.21
36.7 kDa
Required for apoptosis and growth inhibition [8]
Inhibits MST2 activity [93]
Modulates the MAP kinase signal downstream of
the Ras signal [77]
K-Ras [8]
ST1, MST2 [177]
MST1 [75]
Not available
5A (Nore1A) 1q32
47.1 kDa
Suppresses tumour growth via apoptosis induction
or cell cycle delay [7,82]
Regulates microtubule formation [182]
Induces degradation of HIPK1 oncoprotein [183]
Required for the TNFa mediated apoptosis and full
activation of MST1 [80]
Ras, Carma1 [182,184]
MST1 [43,177]
MST2 [177]
tubulin, Aurora A [182]
Mdm2 [183]
Itch [185]
Yes [80]
resistant to TNFa-induced apoptosis,
fail to activate Mst1 in vivo
5C (Nore1B, RAPL) 1q32
30.4 kDa
Regulates lymphocyte adhesion, T cell migration, T
cell receptor regulation [84,86,186]
Controls the directional migration of vascular
endothelial cells [6]
Ras, Carma1 [184]
Rap1, Rap2, MST1
[6,84,86,186]
Yes [86]
impaired lymphocyte trafﬁcking and
lymphoid organ abnormalities
6 4q13
43.4 kDa
Regulates apoptosis [87,93,94]
Regulates cell cycle [94]
Suppresses NFjB pathway [87,187]
Stabilizes p53 [94]
Potentially plays a role in the inﬂammatory
response to respiratory syncytial virus-induced
bronchiolitis [87,88]
Possible obesity regulator [149]
MST2 [93]
K-Ras, MOAP-1 [87]
MST1, MST2 [177]
MDM2 [94]
Not available
7 11p15
39.9 kDa
Regulates cell growth and mitosis [102,103]
Has anti apoptotic activity [104]
N-Ras [104]
MST1, MST2 [177]
CHMP1B, DISC1 [3]
Not available
8 12p12
48.3 kDa
Inhibits cell growth, regulates Wnt and NFjB
pathways, regulates cell–cell adhesion [4]
14-3-3c, FRMD4A,
PSMD4 [3]
Not available
9 12q21.31
50.0 kDa
Possible role in endosome recycling [110]
Essential for epidermal homeostasis [112]
Peptidylglycine a-
amidating
monooxygenase [111]
N-, K- and R-Ras [188]
(contradicts to [177])
Yes [112]
alopecia, shorter life expectancy and
growth retardation
10 11p15
56.9 kDa
Suppress tumor cell growth [189,190]
Induces apoptosis, inhibits Wnt/b-catenin pathway
[116]
None described Not available
The table summarizes current knowledge of the RASSFs with their chromosomal location, protein molecular weights (MW), biological functions, association partners and
genetic knockouts.
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Among the RASSF1 subtypes, 1A and 1C are the most extensively
studied members with both localized to microtubules and involved
in regulation of growth and migration [14,15]. Whereas RASSF1C
may promote the proliferative capacity of cancer cells (especially
breast and lung cancer cells) [16–18], RASSF1A is a bona ﬁde tumor
suppressor [1,2]. Thus, despite harboring 60% amino acid identity
(mainly after amino acid 121 of RASSF1A), RASSF1A and RASSF1C
display distinctive biological properties.
Several groups have demonstrated the importance of RASSF1A
for microtubule stability and have mapped residues important for
this function [10,14,19–21]. RASSF1A interacts with microtubules
though interaction with microtubule associated proteins, such as
MAP1B (microtubule-associated protein 1B) and MAP1S (microtu-
bule-associated protein 1S) [14]. The loss of RASSF1A microtubule
localization results in the inhibition of tumor suppressor proper-
ties, loss of tubulin stability, inhibition of death receptor-depen-
dent cell death and promotion of genomic instability through
the loss of centrosome and mitotic spindle body structures
[14,19,20]. One of the possible mechanisms of microtubule stabil-
ization by RASSF1A involves RAN GTPase [22], and another mech-
anism discovered recently includes the suppression of histone
deacetylase 6 which functions as a tubulin deacetylase [23]. The
ability of RASSF1A to regulate microtubule stability, spindle
assembly and chromosome attachment determine RASSF1A tu-
mor suppressor functions towards controlling cell growth, trans-
formation, motility and invasiveness [15,19,24].
Further studies have shown that interaction of RASSF1A with
RABP1 (RASSF1A binding protein 1/C19ORF5/MAP1S) leads to its
recruitment to the spindle poles in pro-metaphase and its inter-
action with Cdc20 [25] (please note that here is a contradictory
report on RASSF1A interaction with Cdc20 [26]), inhibition of
APC (anaphase promoting complex), accumulation of mitotic cyc-
lins A and B and eventually mitotic arrest [25,27,28]. Upon phos-
phorylation by Aurora A, RASSF1A fails to interact with Cdc20
thereby relieving APC inhibition, leading to degradation of cyclins
and mitotic progression [29]. Interestingly, RABP1/MAP1S was re-
cently shown to enhance autophagy by suppressing genomic
instability and tumorigenesis [30]. Furthermore, it has also been
suggested that RASSF1A stabilization of microtubules may have
a role in autophagy regulation [30].
Along with mitotic progression, RASSF1A was shown to regulate
other aspects of the cell cycle. RASSF1A inhibits accumulation of
cyclin D1 (possibly through JNK kinase pathway [31,32], suppres-
sion of AP-1 activity [27], or both) and blocks the cell cycle at
the G1/S-phase [31,32]. RASSF1A was also shown to associate with
and increase the activity of p120E4F, a transcription factor known to
bind the cyclin A2 promoter [33,34] and p21Cip/Waf1 cyclin-depen-
dent kinase inhibitor [35]. Another mechanism by which RASSF1A
controls cell cycle and apoptosis is by the disruption of the MDM2–
DAXX–HAUSP complex leading to MDM2 self-ubiquitination and
stabilization of p53 [36].
The role of RASSF1A in b-catenin signaling pathway was shown
using Apc+/Min mice, a model of intestinal tumorigenesis. Mutations
of the adenomatous polyposis coli (APC) gene are a frequent and
early event in colorectal cancers. APC inactivation leads to reduced
b-catenin degradation and its nuclear accumulation, thus causing
aberrant Wnt pathway signaling and adenoma initiation [37,38].
It was shown that loss of RASSF1A in Apc+/Min mice resulted in a
signiﬁcant increase in adenomas of the small intestine and
accelerated intestinal tumorigenesis [39]. Immunohistochemical
analysis revealed increased nuclear accumulation of b-catenin in
Rassf1a/; Apc+/Min mice, supporting a mechanistic link via loss
of the known interaction of RASSF1A with b-TrCP that mediates
degradation of b-catenin [39].We have demonstrated the importance of RASSF1A in death
receptor dependent cell death via associations with TNF-R1,
TRAIL-R1 and modulator of apoptosis (MOAP-1) [40,41]. In addi-
tion, RASSF1A can also associate with the pro-apoptotic kinase,
MST1/2 to modulate its kinase activity and promote cell death
[9,42–45]. These associations function to prevent excessive growth
and allow RASSF1A to function as a tumor suppressor. We also re-
cently demonstrated that, under conditions of acute intestinal
inﬂammation, RASSF1A restricts NFjB activity by interfering with
the ability of the membrane proximal TLR/MyD88/TRAF6/IRAK2/4
complex to promote downstream signaling to NFjB [46]. The
restriction of NFjB activity also led to restriction of tyrosine (Y)
357 phosphorylation of Yes associated protein (YAP), a key Hip-
po-dependent transcription factor linked to proliferation [46]. We
determined that Y357 phosphorylation of YAP may arise due to in-
creased inﬂammation and DNA damage – both of which are prom-
inent during intestinal inﬂammation injury stimulated by the
colonic irritant, dextran sodium sulfate (DSS) [46]. We are cur-
rently exploring the molecular mechanisms modulating the Y357
phosphorylation of YAP and of its importance for the appearance
and/or progression of inﬂammatory bowel disease.
Rassf1a/ mice (on the C57BL/6 background) are viable, fertile
and retain expression of isoform 1C and other RASSF gene family
members. They have an increased tumor incidence by 12–
16 months of age (especially in the breast, lung, gastrointestinal
(GI) and immune system [B-cell related lymphomas]) and develop
tumors in response to chemical carcinogens [47,48]. When
Rassf1a/ mice were subjected to cardiac stress by pressure over-
load they responded with an exaggerated hypertrophic response
with the formation of enlarged cardiac myocytes and hearts.
Forced expression of RASSF1A in rat neonatal cardiac myocytes
suppressed Raf-1 and ERK1/2 activation and inhibition of phenyl-
ephrine-induced cardiac myocyte growth [49]. Rassf1a/ mice re-
vealed surprising cell speciﬁcity of RASSF1A signaling in the heart
with cardiomyocytes and ﬁbroblasts showing different signaling
responses. In cardiomyocytes RASSF1A primarily induced apopto-
sis and inhibited hypertrophic cell growth. In cardiac ﬁbroblasts,
however, RASSF1A repressed NFjB activity and inhibited TNFa
secretion, preventing paracrine hypertrophic signaling between
ﬁbroblasts and myocytes [50]. For more detailed discussion of
RASSF1A regulatory mechanisms in the heart please see recent re-
view by Duan et al. [51].
Recently, we showed that Rassf1a/ mice are susceptible to
DSS-induced colitis [46]. Rassf1a/ mice displayed clinical symp-
toms of inﬂammatory bowel disease (IBD) including increased
intestinal permeability, enhanced cytokine/chemokine production,
elevated NFjB activity and elevated colonic cell death and epithe-
lial cell injury [46]. Aged Rassf1a-null mice have an enhanced sus-
ceptibility to spontaneous inﬂammation at >6 months of age (S.
Baksh, unpublished observations) and megaesophagus [52]. Histo-
logical examination revealed chronic inﬂammatory inﬁltrate and
subsequent ﬁbrosis of the myenteric plexus and the muscle layers
[52]. These studies support a role of RASSF1A in modulating NFjB
activity and in restricting uncontrolled inﬂammation leading to
several disease states.
2.2. RASSF1C
As mentioned earlier, in contrast to RASSF1A, RASSF1C does not
have tumor suppressor properties with increasing evidence sug-
gesting that it functions as an oncogene. Overexpression of
RASSF1C in breast cancer cells resulted in enhanced cell migra-
tion/invasion [17]. It was also reported that RASSF1C could activate
osteoblast cell proliferation through interaction with IGFBP-5 [18].
It was shown recently that RASSF1C is a very unstable protein
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mal conditions. Upon DNA damage Mule as well as SFCb-TrCP are in-
volved in the RASSF1C degradation [53]. The association of
RASSF1C with SFCb-TrCP ligase was also described previously in a
study whereby the authors showed that b-catenin accumulation
was promoted either by the overexpression of RASSF1C (which
inhibited b-catenin degradation) or by the silencing of RASSF1A,
implying that the balance between the two isoforms is crucial for
the bTrCP-mediated degradation of b-catenin [5].
RASSF1C has been shown to form a complex with DAXX and
localize to promyelocytic leukaemia-nuclear bodies in the nucleus.
Upon DNA damage DAXX is degraded and RASSF1C is released into
the cytoplasmwhere it activates the SAPK/JNK pathway [54]. Using
yeast two-hybrid system, Chen et al. found that RASSF1C may also
interact and co-localize in the nucleus with tissue factor pathway
inhibitor-2 (TFPI-2), a serine-proteinase inhibitor implicated in
inﬂammation, angiogenesis and tumor growth/metastasis, sug-
gesting other potential roles for RASSF1C [56]. To date, no known
Rassf1c knockout mouse has been established.
2.3. RASSF2
The RASSF2 gene is transcribed into two major isoforms (A and
C) that lack the C1 and ATM domains present in RASSF1A (Re-
viewed in [2]). It is primarily a nuclear protein unlike RASSF1A
and 1C [57]. Promoter methylation and loss of expression of
RASSF2 has been reported in different cancers and cancer cell lines
[58–61] implicating the correlation and signiﬁcance of RASSF2 in
tumorigenesis. In addition, transient expression of RASSF2 in
293T embryonic kidney cells showed prominent growth inhibition
enhanced by activated K-Ras [62]. Furthermore, in situ staining and
ﬂuorescent microscopy illustrated that the attenuation of cell
growth in RASSF2 expression systems was the resultant effect of
apoptosis [62]. Regulation of cell growth by RASSF2 was reported
to be mediated by the MAPK pathway. It was shown that MAPK/
ERK-2 mediated phosphorylation promotes efﬁcient export of
RASSF2 from the nucleus via CRM-1 dependent nuclear export
pathway. A RASSF2 mutant defective in nuclear import failed to ar-
rest the cell cycle at G1/S phase and apoptosis suggesting that nu-
clear retention is critical for RASSF2 mediated cell growth
regulation and therefore tumor suppression [63]. It also appears
that RASSF2 plays an essential role in the nuclear localization of
prostate apoptosis response protein 4 (PAR-4) [64] which must
be translocated to the nucleus to induce apoptosis [65].
It has also been demonstrated that MST1 regulates RASSF2 pro-
tein stability. Knockdown of MST1 in cancer cells destabilized
RASSF2, and Mst1-deﬁcient mice revealed reduced RASSF2 protein
levels. Conversely, RASSF2 complexes with MST1 and activates
MST1 resulting in MST–FOXO3 signaling pathway inhibition.
RASSF2 also engages the JNK pathway and induces apoptosis in
an MST1-independent manner [66]. RASSF2-deﬁcient mice have
bone remodeling defects and it was proposed that RASSF2 regu-
lates osteoblast and osteoclast differentiation by inhibiting NFjB
signaling via limiting IKK activity [67].
2.4. RASSF3
RASSF3 has a 60% amino acid homology to RASSF1A [68] and
can be found in both normal and tumor cells [68]. It is the smallest
member of the C-terminal RASSF family of proteins. It has a CpG is-
land in the promoter but its hypermethylation was only recently
detected in a pituitary somatotroph adenoma [69]. RASSF3 expres-
sion levels were downregulated in 125 of a total 140 non-small-
cell lung carcinomas (NSCLCs), however, DNA hypermethylation
was found not to be a cause of RASSF3 down regulation [70]. When
RASSF3 was overexpressed in HER2/Neu positive human andmouse breast cancer cell lines, cell proliferation was inhibited
[71] suggesting that RASSF3 has a protective role in tumorigenesis.
On the other hand, RASSF3-knockdown NSCLC cells increased the
migration rate in motility assays compared to the control cells
[70]. It was recently shown that RASSF3 expression induces p53
stabilization by facilitating the ubiquitination of MDM2, the E3 li-
gase for p53 [72]. Thus, RASSF3 can exert its tumor suppression
properties via p53-dependent apoptosis and DNA damage control
mechanisms. To date, no known Rassf3 knockout has been
generated.
2.5. RASSF4
RASSF4 has 25% and 60% identity with RASSF1A and RASSF2
respectively [8]. Current studies demonstrate that RASSF4 is
broadly expressed in normal tissues [8,73,74] and the reduction
of RASSF4 expression due to promoter speciﬁc hypermethylation
was detected in tumor cell lines and primary tumors [8,73,74] sug-
gesting that RASSF4 might act as a tumor suppressor. However, a
recent paper revealed a pro-growth role for RASSF4 in alveolar
rhabdomyosarcoma (aRMS) [75]. One of the subtypes of aRMS is
characterized by paired box-3-forkhead box protein O1 (PAX3-
FOXO1) – a chimeric protein, arising as a result of chromosomal
translocation. The expression of PAX3-FOXO1 is associated with
an 8% survival of patients past 4 year [76]. Using cell free models
it was demonstrated that PAX3-FOXO1 transcriptionally upregu-
lates RASSF4 which in turn inhibits cellular senescence and pro-
motes cell proliferation [75]. It was also demonstrated that
RASSF4 interacted with and inhibited the tumor suppressor
MST1/Hippo, suggesting that RASSF4 may act as a Hippo pathway
inhibitor. A further study revealed suppressed Hippo signaling in
aRMS, that was reﬂected in high expression level of YAP (Yes-asso-
ciated protein 1). Although attempts to ﬁnd a clear cause and effect
relationship between YAP and RASSF4 biology failed, YAP was
shown clearly to be involved in senescence regulation [75]. Inter-
estingly, earlier studies have shown that RASSF4 associated di-
rectly with activated K-Ras and induced cell death in 293T
embryonic kidney and MCF-7 breast cancer cells [8], indicating a
tumor suppressor role of RASSF4. However, the human lung tumor
cell line H1299 was completely resistant to RASSF4-mediated
growth inhibition, suggesting cell line dependence of RASSF4 func-
tions [8]. It will be interesting to explore what determines the pro-
or anti-tumor functions of RASSF4. One of the proposed regulators
might be p53 [8], since H1299 cells (but not MCF-7 cells) are defec-
tive for p53. It was also suggested that RASSF4 may suppress the
MAP kinase signal by suppression of ERK phosphorylation [77]
thus providing another possible mechanism for RASSF4-mediated
tumor suppression. To date, no known RASSF4 knockout has been
generated.
2.6. RASSF5
RASSF5 (also called NORE1 or RAPL) was the ﬁrst member of
RASSF proteins to be cloned [78]. It is expressed as three tran-
scripts (A–C) via differential promoter usage and alternative splic-
ing. The longest form of RASSF5A has 40% amino acid similarity
with RASSF1A. RASSF5A has been shown to associate with cyto-
skeletal proteins through its RA domain and promote growth sup-
pression via the ERK pathway [79]. In addition, RASSF5A can
complex with MST1 kinase upon TNF-a and TNF-related apopto-
sis-inducing ligand (TRAIL) stimulation in order to drive apoptosis
[80]. RASSF5A can also heterodimerize with RASSF1A via N-termi-
nal interactions and RASSF5 can associate with Ras-like GTPases to
promote cell death [81]. It has also been demonstrated that RASS-
F5A can inhibit cell proliferation independently of MST1/2 kinases
and Ras-GTPases through a delay in cell cycle progression [82]. The
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role suggests that apoptosis control is a very important function of
RASSF5.
The C57BL/6-Rassf5a/ mice were just recently generated but
do not have an overt phenotype nor evidence of tumor formation
as they age [80]. However, cells from the Rassf5a/ mice were
resistant to TNFa and TRAIL-dependent cell death and reduced
activation of JNK kinases in response to TNFR stimulation failed
to activate MST1 in vivo [80]. In line with the role of RASSF5 as a
tumor suppressor, K-Ras transfected mouse embryonic ﬁbroblasts
developed a signiﬁcant amount of tumors when injected into im-
mune compromised mice to support the role of RASSF5 in restrict-
ing excessive growth [80]. Recently it was demonstrated that
RASSF5A plays a role in developing the nervous system [83].
The shortest RASSF5 isoform RASSF5C/NORE1B/RAPL is ex-
pressed predominantly in lymphoid tissues [84] and was shown
to act as a mediator of the Rap1 induction of integrin clustering
and activation after T-cell receptor stimulation [84], hence it was
named as RAPL (regulator for cell adhesion and polarization en-
riched in lymphoid tissues). Whereas most functional studies were
focused on RASSF5A, there is direct evidence that RASSF5C can
suppress growth and colony formation in cells to the same extent
as RASSF1A (although not in all cell lines tested) [82].
It was shown that RAPL is important for p27 (a regulator of cell
cycle progression) nuclear localization in lymphocytes upon anti-
gen receptor stimulation. RAPL deﬁciency resulted in the cytoplas-
mic localization of p27 and hyperproliferation of both T and B cells.
RAPL-deﬁcient mice developed lupus-like autoimmunity and B cell
lymphomas, suggesting that the regulation of p27 subcellular
localization by RAPL serves as a checkpoint for S phase entry to
prevent immunoproliferative disorders [85]. Mice deﬁcient in
RASSF5C exhibited impaired lymphocyte trafﬁcking and lymphoid
organ abnormalities [86].
2.7. RASSF6
A few years following the discovery of RASSF1, a new Ras effec-
tor protein, RASSF6 showing similar structural topography to that
of other RASSF proteins, was characterized and mapped [87,88].
To date, three isoforms of RASSF6 (A–C) have been identiﬁed (re-
viewed by [89]). Similar to other RASSFs, RASSF6 behaves like a tu-
mor suppressor protein and is epigenetically silenced in childhood
leukaemias and neuroblastomas [90,91]. Overexpression of RASSF6
in HeLa cells induced apoptosis via a signaling mechanism that is
associated with Bax activation and cytochrome c release [92]. Fur-
thermore, RASSF6 and MST2 inhibited each other under basal con-
ditions but dissociated upon stimulation resulting in apoptosis in a
RASSF6-WW45-dependent manner. However, the authors also
demonstrated that RASSF6 was able to induce apoptosis in a paral-
lel WW45-independent manner. RASSF6 association with MST2
inhibits canonical Hippo pathway activation [93]. Interestingly, it
was demonstrated that RASSF6 binds to MDM2 and facilitates its
self ubiquitination and degradation, stabilizing p53 (like RASSF1A
and RASSF3), thereby regulating apoptosis and cell cycle [94]. It
also has been demonstrated that, similar to RASSF1A and RASSF2,
RASSF6 can inhibit NFjB activity and possibly inﬂammation by un-
known mechanisms [87]. To date, no known Rassf6 knockout
mouse has been generated.
2.8. RASSF7
In 1994 Weitzel and Patel identiﬁed an aggregate of genes on
chromosome 11p15, surrounding HRAS1 cluster 1 [95]. The up-
stream gene was originally named HRC1 (HRAS1-related cluster
protein1) and was later renamed as RASSF7. Due to alternative
splicing, RASSF7 is comprised of three transcripts (A–C) containingan N-terminal RA domain but lacking the SARAH domain con-
served among RASSF1–6 family members [89]. RASSF7 is ubiqui-
tously expressed in many tissues, speciﬁcally in brain, lung, and
human cell lines and is up regulated in several carcinomas such
as islet cell tumors [96], pancreatic ductal carcinoma [97–99],
endometrial cancer [100] and ovarian clear cell carcinomas [101].
Protein and mRNA expression of RASSF7 was shown to be en-
hanced upon hypoxic insults [102] which, given the hypoxic nature
of solid tumours, might explain the increase in RASSF7 expression
seen in tumor cells. No promoter methylation of the RASSF7 gene
was found in 57 cancer cell lines in the study by Recino et al.
[102]. Conversely, Djos et al. reported that CpG island of the
RASSF7 gene was heavily methylated in neuroblastoma cell lines
suggesting that RASSF7 may be involved in the regulation of tumor
formation [90]. Functional analyses demonstrated that RASSF7 in-
duces cell growth through the regulation of spindle formation sub-
sequently promoting mitotic progression [102,103]. A recent study
illustrated the role of RASSF7 in cell survival during periods of
stress. During initial stress, RASSF7 associates with N-Ras, inhibit-
ing MKK7/JNK signaling pathway and inducing cell growth [104].
However, the anti-apoptotic property of RASSF7 is soon lost fol-
lowing prolonged exposure of UV radiation, due to degradation
of RASSF7 through ubiquitination [104]. Thus, the mounting evi-
dence so far argues a tumor suppressor function for this RASSF pro-
tein. Currently, no known Rassf7 knockout has been generated.
2.9. RASSF8
Seven transcripts of RASSF8 have been identiﬁed so far [89].
Similarly to RASSF7, RASSF8 isoforms contain an N-terminal RA do-
main and lacks the SARAH region [89]. The tumor suppressor role
of RASSF8 was initially proposed due to reduced transcript levels of
RASSF8 in lung adenocarcinomas [105]. Loss of RASSF8 does not
appear to be due to promoter methylation, except possibly in
childhood leukemia [91] and the mechanism for RASSF8 down-reg-
ulation in many cancers remains to be elucidated. Further studies
demonstrated that transient expression of RASSF8 in lung carci-
noma cells attenuated cell growth in soft agar [105]. Collectively,
these ﬁndings support the notion that RASSF8 regulates tumor
development. Additional functions of RASSF8 include cell–cell
adhesion due to its association with adherens junction linked to
b-catenin/E-cadherin function [4]. Wound healing assays exhibited
increased cell migration in cells lacking RASSF8 expression, sug-
gesting that loss of RASSF8 may contribute to tumor aggressive-
ness [4]. However, serum analysis indicated that mRNA levels of
RASSF8 in blood plasma were elevated in breast cancer patients
in comparison to healthy controls [106], suggesting a tumor pro-
moter effect of RASSF8. Early studies demonstrated that RASSF8
interacts with the adapter protein 14-3-3 [107], an ubiquitously
expressed scaffolding protein that regulates various molecular pro-
cesses including apoptosis and cell cycle progression [108]. Inter-
estingly, RASSF1A-mediated cell death can be regulated by 14-3-
3 as well [109]. Thus, these adapter proteins appear to be pivotal
in the functional regulation of RASSF proteins. To date, no known
Rassf8 knockout has been generated.
2.10. RASSF9
RASSF9 was previously known as P-CIP1, peptidylglycine a-
amidating monooxygenase COOH-terminal interactor protein-1
and regulates the distribution and ultimate fate of peptidylglycine
alpha-amidating monooxygenase in endosomal pathways
[110,111]. However, following BLAST analysis, P-CIP1 revealed
similar structural homology to RASSF7 and RASSF8 and was later
named RASSF9 [3]. RASSF9 contains the conserved RA domain
localized at the C-terminus similarly to RASSF7, 8 and 10 [3]. Little
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RASSF9. In 2011, Chang’s group reported the predominant expres-
sion of RASSF9 in epithelial tissue [112]. Rassf9-deﬁcient mice
exhibited signs of senescence including increased alopecia, shorter
life expectancy and growth retardation, implicating its role in epi-
dermal development [112].
2.11. RASSF10
RASSF10 shares similar structural features to that of RASSF7–9,
whereby it comprises an N-terminal RA domain and lacks the SAR-
AH region [91]. RASSF10 was shown to be expressed in bone mar-
row as well as thyroid, brain, prostate and kidney [91,113–115].
Concomitantly, hypermethylation of RASSF10 was associated with
loss of gene and protein expression in cancer conditions such as
childhood leukaemias, thyroid carcinomas and gliomas
[91,113,114]. The transcription of RASSF10 was restored using a
demethylating agent [116]. In vitro analyses in U87 glioma cells
treated with RNAi to knockdown RASSF10 expression, showed in-
creased cell proliferation and cell survival [113]. Re-expression of
RASSF10 in these cells inhibited cell growth and colony formation
of glioma cells highlighting the tumor suppressor function of
RASSF10 [113]. More recently, the tumor suppressor activity of
RASSF10 was assessed in gastric cancer cells, demonstrating that
reintroduction of RASSF10 in gastric cell lines JRST and BGC823 re-
duced cell viability and promoted apoptosis [116]. The pro-apopto-
tic nature of RASSF10 was shown to involve the Wnt/b-catenin
signaling pathway [116]. Additionally, RASSF10 may play a poten-
tial role in the regulation of mitotic progression due to its localiza-
tion to centrosomes and microtubule association [113]. In light of
the existing information, it appears that RASSF10 is a strong candi-
date as a prognostic marker to screen certain carcinomas.3. Epigenetic regulation of the RASSFs
Epigenetics has now emerged as a key driver of disease states
such as cardiovascular diseases, cancer, and schizophrenia. It is a
mechanism that results in the changes of gene expression without
an underlying change in the nucleotide sequence or in the ability of
the organism to transfer the change to the next generation.
Although epigenetic changes are not directly transferred to the
next generation, in most cases the susceptibility for change to oc-
cur in a speciﬁc region is transferred and thus can have familial
links.
Epigenetic changes can be in the form of histone modiﬁcation
leading to chromatin remodeling or by the conversion of cytosine
to 5-methylcytosine. The latter occurs on speciﬁc CG-rich DNA
stretches termed ‘‘CpG islands’’ within the promoter region and
interferes with normal transcription [117,118]. DNA methylation
is maintained by DNA methyltransferase 1 (DNMT1), which pre-
dominantly methylates hemi-methylated DNA. DMNT3a and
DNMT3b methyltransferases are responsible for de novo methyla-
tion of unmethylated CpG. Although methylation is a drastic
change, it can be reversed with the use of 5-Aza-20-deoxycytidine
(a cytidine analog that inhibits DNA methylation) [119]. However,
the use of 5-Aza-20-deoxycytidine has its limitations and targeted
delivery to the affected area has posed challenges for its use as a
potential therapeutic agent.
As mentioned earlier, several RASSF family members are regu-
lated by promoter speciﬁc epigenetic changes. RASSF1A was the
ﬁrst to be identiﬁed and is considered to be one of the most meth-
ylated genes in human cancer. Not only is it epigenetically silenced
in numerous cancers but it is considered as one of the earliest
detectable changes in cancer [120]. Reports show that epigenetic
silencing of RASSF1A occurs at a prevalence of 10–30% in cervicalcancer, 60% in breast cancers to 80% in small cell lung cancer and
up to 99% in prostate cancer (see Table 3 for the complete list
and references). Epigenetic modiﬁcations occur on >60 CpG sites
spanning the RASSF1A promoter and exon 1. Silencing can be de-
tected in numerous cell lines and can be reversed using 5-aza-20-
deoxycytidine, machanine [76], curcumin [121] or the approved
FDA drug for treating acute myeloid leukemia, decitabine.
The correlation of RASSF1A methylation with different tumor
characteristics has been reported by several groups. RASSF1A pro-
moter methylation correlated inversely with K-Ras and B-Raf
mutation status in cervical adenocarcinomas [122] and thyroid
cancers [123–125]. RASSF1A methylation was also shown recently
to inversely correlate with TP53 mutations [120], suggesting that
they likely have independent mechanisms in tumourigenesis. A po-
sitive correlation between the degree of RASSF1A methylation and
higher tumor grade [51,120], the ability of deeper myometrial
invasion and positive metastatic involvement of pelvic lymph
nodes in endometrial cancer was reported [51]. Interestingly RASS-
F1A hypermethylation correlated with chromosome instability in
Wilm’s tumors [126] supporting a role for RASS1A in controlling
genomic stability. Subtype-speciﬁc difference in methylation was
described in lung cancer with lower methylation of RASSF1A de-
scribed for NSCLC and higher for SCLC (Table 2). In breast cancer,
it was shown that RASSF1A has a higher methylation level in
HER2 positive compared to HER2-negative breast tumors [120].
Interestingly, in acute myeloid leukemia, RASSF1A methylation
occurs very rarely if ever (please see Table 1 in [127]) and RASSF1A
expression is not affected [128] suggesting that RASSF1A is not in-
volved in the pathogenesis. It will be interesting to determine why
RASSF1A, which is methylated in such an extent in other tumors,
remains intact in myeloid malignancy. It might be possible that
other RASSFs such as RASSF6, 7 or 10 (please see Table 2) epige-
netic silencing is responsible for leukemia’s development.
With the advantage of pyrosequencing we can now study pro-
moter methylation with greater detail, gaining information about
the degree of methylation of individual CpG sites. Pyrosequencing
revealed high variability of a distribution and level of RASSF1A pro-
moter methylation within and among pancreatic cancer samples
[129]. The same variability was shown ten years earlier in breast
cancer using an oligonucleotide-based microarray technique
[130]. Based on the detailed data, Yan et al. concluded that RASSF1A
promoter is characterized by progressive accumulation of methyl-
ation starting from the ﬁrst exon to the promoter area of the RASS-
F1A gene [130].
Besides cancer, epigenetic silencing of RASSF1A has been ob-
served in ulcerative colitis (UC) patients [131], a form of inﬂamma-
tory bowel disease (IBD). UC and Crohn’s disease (CD) are chronic
intestinal idiopathic diseases characterized by inﬂammation of the
GI tract resulting in abdominal pain, chronic diarrhea, and weight
loss. Molecularly, inﬂammation is characterized by the hyperacti-
vation of transcription factors such as NFjB and elevated produc-
tion of cytokines to amplify the inﬂammatory response [132–
134]. The activation of NFjB can originate from multiple surface
receptors including Toll like receptors (TLR) or tumor necrosis fac-
tor a (TNFa) receptor (TNF-R1) that will ultimately result in cyto-
kine production, such as IL-6 production. Interestingly, IL-6 can
drive epigenetic loss of RASSF1A via DNA methyltransferase 1
(DNMT1) up-regulation [135,136] suggesting that inﬂammation
can drive expression loss of RASSF1A and may explain why UC pa-
tients have epigenetic loss of RASSF1A. Importantly, IBD patients
show an increased likelihood of developing colorectal cancer later
in life and RASSF1A promoter methylation has been observed in
colorectal cancers, suggesting that RASSF1A loss may be an early
event in colorectal cancer development [131]. A similar epigenetic
silencing of RASSF1A can be detected in 44% of pancreatitis pa-
tients [137] and it is known that inﬂammation of the pancreas is
Table 2
This is a summary of the articles describing RASSFs promoter methylation investigated in various cancer types. The percentage of patient samples methylated in the indicated
cancers are shown.
Gene Cancer type Percentage (where possible) and References
RASSF1A Adrenocortical carcinoma 60% [S1]
Endometrial cancer 85% [S2]
Ewing sarcoma 68% [S3], 53% [S4]
Hepatoblasoma 44% [S5]
Merkel cell carcinoma 51% [S6]
Papillary thyroid carcinoma [S7]*
Parathyroid tumors 52% [S8]
Pituitary adenomas 20–50% [S9]
RASSF2 Breast cancer 38% [S10]
Colorectal cancer 42% [S11]
Ewing sarcoma [S4]*
Gastric cancer Up to 80% [S12]
Lung cancer (NSCLC) 31% [S13], 44% [S10]
Merkel cell carcinoma 7% [S14]
Nasopharyngeal carcinoma 51% [S15]
Oral squamous cell carcinoma 26% [S16]
Prostate cancer 67% [S17]
Squamous cervical cancer 61% [S18]
Thyroid cancer 63% [S19]
RASSF3 Somatotroph adenoma [S20]*
RASSF4 Breast cancer 27% [S21], 54% of breast cancer cell lines [S21]
Hepatocellular carcinomas 5% [S22]
Kidney cancer 44% of renal cell carcinoma cell lines [S21]
Lung cancer 21% in SCLC, 22% NSCLC [S21, 23]
Nasopharyngeal cancer 5% [S24]
RASSF5A Colorectal cancer 39% [S25]
Pheochromocytoma and abdominal paraganglioma [S25]*
RASSF5C Hepatocellular carcinomas 62% [S26]
Merkel cell carcinoma 8% [S14]
RASSF6 Childhood leukemia 94% of B-ALL [S27], 41% of T-ALL [S27]
Neuroblastoma [S28]*
RASSF7 Chronic lymphocytic leukemia 16% [S29]
Neuroblastoma [S28]*
RASSF8 Childhood leukemia 9% of B-ALL [S27], 10% of T-ALL [S27]
Lung adenocarcinoma in mice [S20]*
RASSF10 Childhood leukemia 16% of B-ALL [S27], 88% of T-ALL [S27]
Chronic lymphocytic leukemia 50% [S29]
Glioblastoma [S30]*
Melanoma 68% [S31]
Merkel cell carcinoma 23% [S14]
Prostate carcinoma [S32]*
Thyroid cancer 66% [S33]
For additional data for RASSF1A and RASSF5A please see [127], only new data are presented here. Note that RASSF1C CpG island hypermethylation has never been described.
Please note that due to references number restriction references to this table are placed into online Supplementary materials.
This is a summary of the articles describing RASSFs promoter methylation investigated in various cancer types. The percentage of patient samples methylated in the indicated
cancers are shown.
* For these studies, pyrosequencing was used to determine methylation status with no indication of% prevalence indicated in the reference. The study only detected a degree
of RASSF1A methylation and it was greater in patients compared to controls utilized.
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83% of patients have RASSF1A epigenetic silencing [137]. Thus, the
epigenetic loss of RASSF1A during a pre-cancer state (inﬂamma-
tion) may represent a molecular mechanism whereby chronic
inﬂammation drives epigenetic silencing of the RASSF1A in order
to promote malignancy.
Because the epigenetic loss of RASSF1A has been detected in
numerous disease settings, there are several patents to utilize epi-
genetic loss of RASSF1A as a diagnostic tool for disease appearance
(please see http://www.google.co.in/patents/US6596488; http://
www.google.com.tr/patents/WO2013041731A1?cl=en; http://
www.google.com/patents/US8546078). Epigenetic loss of RASSF1A
has been observed in urine [138–140], nipple aspirates [141,142],
and sputum [143] to mention a few. Thus, there is potential in uti-
lizing epigenetic loss of RASSF1A as a diagnostic/prognostic tool for
treating cancer and potentially other diseases as well. For example,
the signiﬁcant increase in the hypermethylation of RASSF1A in
plasma of pregnant women with intrahepatic cholestasis was sug-
gested as a diagnostic marker of this disease state [144].The 50 CpG island of RASSF2 spans approximately 1.6 kb and
RASSF2 has been shown to undergo epigenetic silencing in 88% of
thyroid cancer patients, with 63% of these patients also showing
RASSF5A epigenetic silencing [145]. Epigenetic silencing was not
observed in patients with goiter or follicular adenomas. In the
same samples, RASSF3 and 4 were not epigenetically silenced but
RASSF5A was, suggesting selective roles for RASSF2 and 5A in the
function of the thyroid gland. Furthermore, 5-aza-20-deoxycytidine
treatment was able to restore the expression of RASSF2 and 5A in a
thyroid cancer cell line. RASSF2 methylation was also detected in
colorectal cancer (CRC), gastric cancer and oral squamous cell car-
cinoma (please see Table 2 for the complete list and references). In
squamous cervical cancer RASSF2 hypermethylation was associ-
ated with shorter survival time [146]. Interestingly, in CRC patients
the histone modiﬁcation epigenetic mechanism was probably also
involved in silencing of RASSF2, because treating cells with a his-
tone deacetylase inhibitor augmented RASSF2 expression [58].
Promoter methylation of RASSF3 is rarely detected in cancer and
was only described just recently in somatotroph adenoma
Table 3
RASSF1A kinases.
Kinase Amino acid
residue
RASSF1A function affected References
Aurora A T202 and/or
S203
Phosphorylation disrupts RASSF1A interactions with microtubules and abolishes RASSF1A ability to
induce M-phase cell cycle arrest.
Phosphorylation leads to dissociation of RASSF1A from Cdc20, which allows for APC interaction with
Cdc20, Cyclin A reduction and pro-metaphase progression
[29,165]
Aurora B S203 Phosphorylation leads to interaction with Syntaxin16 and localization of Syntaxin16 to the midzone
and midbody in late mitosis, and thus the completion of cytokinesis
[169]
Cyclin D Cyclin dependent
kinase 4 (Cyclin D-CDK4)
S203 Phosphorylation is required for Skp2 dependent degradation of RASSF1A [166]
Chk1 (checkpoint kinase) S184 Phosphorylation causes RASSF1A to dissociate frommicrotubules and alters RASSF1A distribution in the
cell, with ‘‘punctate distribution pattern’’, not ‘‘network and ﬁber-like’’. RASSF1A phosphorylation
mimicking mutant abolishes the ability of RASSF1A to induce M-phase arrest
[170]
ATM (Ataxia telangiectasia
mutated)
S131 Phosphorylation is required for the activation of MST2 and LATS1, which leads to p73 stabilization [11]
PKC (Protein kinase C) S197 and
S203
Phosphorylation is required for the ability of RASSF1A to reorganize the microtubule network [167]
MST1 (Mammalian STE20-like
kinase 1)
T202 and
S203
Phosphorylation is required for the capacity of the RASSF1A to activate NDR1/2 [168]
GSK-3b (Glycogen synthase
kinase 3b)
S175, S178,
and S179
Phosphorylation is required for RASSF1A association with 14-3-3 to inhibit association with TNF-R1 or
TRAIL-R1
[109]
This table summarizes what is known about identiﬁed kinases for RASSF1A and, when known, how it affects RASSF1A biology.
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study has shown that some polymorphisms can predispose to
squamous cell carcinoma of the head and neck by modifying
RASSF3 expression levels [147], providing another way of RASSF3
regulation.
Methylation of RASSF4 promoter in head and neck squamous
cell carcinomas (HNSCC) was rather infrequent (13%, n = 54) [73]
and a low methylation frequency (5%) was also reported for naso-
pharyngeal cancer [74]. However, a trend for higher RASSF4 meth-
ylation was detected in recurrent HNSCC. This correlates with a
recent ﬁnding that RASSF4 expression was suppressed in a subpop-
ulation of oral cancer stem-like cells/cancer-initiating cells [77],
suggesting that RASSF4 plays a role in cell migration and invasive-
ness control.
Early studies demonstrated loss of RASSF5A expression in lung
tumor cell lines and primary lung tumors [7], Wilms’ tumor and re-
nal cell carcinoma, colon cancer, as an apparent result of promoter
speciﬁc hypermethylation (please see Table 2 for the complete list
and references). Alternative to epigenetic silencing, RASSF5A can be
downregulated through proteolysis catalyzed by calpain proteins,
offering a means for tumor cells to ﬂourish and escape growth inhi-
bition [148]. RASSF5C promoter methylation is a rare event, possi-
bly because its expression is limited to lymphoid tissue.
Interestingly, it only has been detected in hepatocellular carcinoma
and 8% of Merkel Cell Carcinoma (please see Table 2 for the com-
plete list and references).
Similar to RASSF5, RASSF6 has been found to be epigenetically si-
lenced in neuroblastoma [90] and childhood leukemia [91]. RASSF6
was found to be down-regulated by interactions with macrophages
in vitro [149] to suggest that the immune system plays a role in
regulation of RASSF6.
RASSF10 is another member of the RASSF family of proteins that
is also epigenetically silenced. To date, 68% of malignant melanoma
patient samples tested harbor epigenetically silenced RASSF10
[150]. In addition, RASSF10 promoter methylation has been ob-
served in prostate cancer patients as well as up to 88% of paediatric
leukemias, 50% of chronic lymphocytic leukemia, 66% of thyroid
cancers, and 68% of melanoma (please see Table 2 for the complete
list and references).
Not many reports exist currently on methylation of RASSF7 and
8 (see Table 2) and RASSF9 gene does not contain CpG island.Although it is clear that epigenetics plays a crucial role in the
regulation of expression of the RASSF proteins, the underlying
mechanisms just started to emerge. It was shown recently that
RASSF1A promoter methylation is regulated by p53 and death-
associated protein 6 (DAXX) [151]. The authors have found that
p53 binds to the RASSF1A promoter, recruits DAXX and DNMT1,
leading to DNA methylation and subsequently to inactivation of
RASSF1A. Interestingly, ﬂuctuation in p53 protein levels did not
affect the rates of RASSF1A methylation. Conversely, methylation
of the RASSF1A promoter was critically controlled by DAXX, as
the enforced overexpression of DAXX led to enhanced RASSF1A
promoter methylation, whereas inhibition of DAXX reduced RASS-
F1A methylation [151].
To better understand the mechanism of RASSF1A epigenetic
silencing, Palakurthy et al. performed a genome-wide RNAi screen
and found that homeobox protein HOXB3 is required for RASSF1A
promoter hypermethylation [152], a ﬁnding which was supported
by a miRNA study later [153]. It appears that HOXB3 binds to the
DMNT3B gene to increase its expression. DNMT3B then is recruited
to the RASSF1A locus through interactions with polycomb repressor
complex 2 (PRC2) and MYC, where it methylates the RASSF1A pro-
moter [152].
Another player involved in epigenetic regulation of RASSF1A
was reported recently [154]. Beckedorff et al. showed that non-
spliced long non-coding RNA transcribed from the antisense strand
of RASSF1A forms an RNA/DNA hybrid at the RASSF1A transcription
site and recruits polycomb repressor complex 2 (PRC2) to the RASS-
F1A promoter. This results in increased methylation of histone
H3K27 at the RASSF1A promoter and speciﬁc reduction of tran-
scriptional activity. No DNA hypermethylation was detected in
RASSF1A promoter in this study.4. Other mechanisms of RASSFs regulation
In this section we will describe several other mechanisms of
RASSF regulation with focus on microRNA and post-translational
modiﬁcations of RASSF1A. Single nucleotide polymorphisms do ex-
ist for RASSF1A as another mechanism responsible for altering the
biology of RASSF1A. This was recently reviewed in detail by Gordon
et al. [155] and will not be discussed here.
Table 4
Summary of transcription factor (TF) binding sites for RASSF genes.
RASSF Potential TF binding sites
N-terminal RASSFs:
RASSF1 NFjB, p53, AP1, c-Jun, HoxA5
RASSF2 NFjB, p53, NFAT, IRF-1, SRY
RASSF3 p53, ITF-2, Tal-1b, c-Myc, Max1, CP1A, NF-Y, CBF(2)
RASSF4 SRF, Pax-5, SRY, HOAA3, E2F, STAT1, STAT2
RASSF5A
(Nore1A)
NFjB, p53, Elk-1
RASSF5C
(Nore1B)
NFjB, p53, AP4, c-Myb
RASSF 6 NFjB, p53, FoxC1, Hlf, FOXO3, RFX1, RelA
C-terminal RASSFs:
RASSF7 NFjB, STAT3, c-Myc, c-Myb, Max-1, NF-1, HNF-1
RASSF8 RORa2, POU3F, POU2F, RSFC4, Cdc5, RFX1
RASSF9 Nkx2, RORa2, CHOP-10, c/EBPa, Lhx3, Pax-4, ER-a, Evi-1,
Olf-1
RASSF10 Cart-1, NRSF, CREB, RFX1, ATF-2, CRE-BP1, FOXO1a, FOXO1,
HNF-3b
The most relevant TF for RASSF genes were gleaned from http://www.gene-
cards.org/ and TFbind program [191].
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MicroRNAs (miRNAs) are short (22 nucleotide) RNAs impor-
tant for the regulation of numerous physiological processes. It ap-
pears that about 60% of human protein coding genes are regulated
by miRNAs [156]. Many miRNAs are epigenetically regulated, asso-
ciated with CpG islands and regulated by histone modiﬁcations. It
is well established that miRNAs are often dysregulated in many
types of cancer, and it has been proposed that miRNAs may func-
tion as either oncogenes or tumor suppressors depending on the
target genes [157,158]. Currently 1872 human miRNAs are regis-
tered in the miRBase database (release 20, June 2013) with many
miRNAs assigned to regulate speciﬁc genes [159].
Bioinformatic analysis (microrna.org) suggests that RASSF1A
mRNA can be targeted by at least ﬁfteen miRNAs (miR-326, -330,
-149, -16, -497, -504, -410, -99a, -99b, -100, -124, -193, -193b,
-182, -181a–d). However the only one so far experimentally vali-
dated is miR-602, which was not predicted. It has been shown re-
cently that inhibition of mir-602 expression in hepatoma cells
increased RASSF1A expression, promoted hepatoma cell apoptosis
and inhibited cell proliferation suggesting that miR-602 had regu-
latory role in early stage of HBV-mediated hepatocarcinogenesis by
inhibiting tumor suppressive functions of RASSF1A [160]. Since
aberrant miR-602 expression was detected in early stages of
hepatocarcinogenesis and correlated with RASSF1a protein loss
the authors suggested that it may be a potential early marker for
that condition (and possibly others) and may serve as a therapeutic
target for HBV-positive hepatocellular carcinoma.
Persistent inﬂammation and increased IL-6 levels have been
shown to up regulate DNMT activity to epigenetically silence genes
such as RASSF1A. We can speculate that microRNA targeting
DNMTs or other proteins involved in epigenetic regulation may
also affect RASSF1A expression. One study revealed that overex-
pressed DNMT1 in colorectal cancer tissues and cell lines was asso-
ciated with downregulated miR-342 [161]. Restoration of miR-342
resulted in a dramatic reduction of the expression of DNMT1 and
this in turn reactivated RASSF1A along with ADAM23, Hint1 and
RECKS genes via promoter demethylation. Li et al. showed de-
creased DNMT3b association with RASSF1a promoter after miR-7
and miR-218 silencing of HOXB3 transcription factor in breast
cancer cells [153]. Additionally, they detected increased histone
acetylation at the RASSF1A promoter. It was demonstrated that
miR-373 is able to regulate RASSF1A expression via MBD2
(Methyl-CpG-Binding Domain Protein 2) in hilar cholangiocarci-
noma. RASSF1A expression increased following suppression of
MBD2 by miR-373 in QBC939 cells, and decreased after activation
of MBD2 by anti-miR-373 inhibitor in HIBEpic cells [162]. Interest-
ingly, in a parallel study the same group revealed that miR-373
gene promoter contained a CpG island and was regulated by meth-
ylation [163]. This phenomenon of miRNA-epigenetics regulatory
networks was reviewed recently [164]. Therefore, these studies
reveal an importance of microRNA regulation of RASSF1A. Theoret-
ically the other RASSF members can also be regulated by miRNAs,
but currently there is no experimental proof of that in the scientiﬁc
literature.
4.2. Post-translational modiﬁcations of RASSF1A
Post-translational modiﬁcations of RASSF1A are described as
the regulatory mechanism that may affect the biological properties
and stability of RASSF1A. RASS1A is known to be phosphorylated at
several serine and threonine residues under physiological condi-
tions. Rong et al. reported that the mitotic kinase Aurora-A directly
interacts with and phosphorylates RASSF1 (on Thr202/Ser203)
during mitosis and this regulates the ability of RASSF1A to interact
with microtubules and modulate cell cycle progression [165].Recently, several other kinases, including ATM (ataxia telangiecta-
sia mutated) [11], CDK4 (cyclin-dependent kinase-4) [166], PKC
(protein kinase C) [167], MST1 [168], Aurora A [165], Aurora-B
[169], and Chk1 [170] have also been shown to phosphorylate
RASSF1A. Each of these kinases seems to regulate different aspects
of RASSF1A function (see Table 3), suggesting that regulation of
RASSF1A by phosphorylation is a complex process with multiple
kinases involved that modulate RASSF1A function needed for
various cellular processes.
As discussed above RASSF1A protein arrests cells in G1 phase
and loss of RASSF1A leads to uncontrolled cell division in cancer.
Since RASSF1A is expressed in normal cells, they have to have a
mechanism to reduce RASSF1A and progress through cell cycle. It
is well known that ubiquitination machinery plays a major role
in regulation of factors important for cell cycle progression (see
Fig. 2 in [171]). It appeared that ubiquitinylating enzyme com-
plexes regulate RASSF1A as well. The Skp1-Cul1-F-box (SCF) ubiq-
uitin ligase complex was the ﬁrst complex discovered to regulate
RASSF1A [166]. The Skp2 subunit of this complex interacts with
RASSF1A and promotes its degradation at the G1-S transition of
the cell cycle. Interestingly, RASSF1A has to be phosphorylated
on Ser202 by cyclin D-cyclin-dependent kinase 4 to be able to
interact with Skp2 [166]. In mitosis, Cullin 4A (CULL4A) promotes
RASSF1A degradation [172]. In this case DNA damage-binding pro-
tein 1 directly interacts with RASSF1A and brings it to the CUL4A
E3 ligase complex during mitosis. Ubiquitination therefore plays
an important role in RASSF1A regulation and defects of ubiquitina-
tion machinery along with lower levels of RASSF1A expression
were shown to be associated with hepatocellular carcinoma prog-
nosis, and this may potentially serve as a diagnostic marker [173].
It was recently shown that the RASSF1A promoter has a p53
binding site 2718 bp upstream from the ATG transcription start co-
don, and that p53 is able to bind to the RASSF1A promoter and in-
hibit RASSF1A expression [174]. A transcription factor (TF) search
revealed that almost all C-terminal RASSF genes (except RASSF4)
have p53 and NFjB (except RASSF3 and 4) binding sites in their
promoters (Table 4). At the same time, N-terminal RASSF genes
have a distinct TF set, suggesting that not only is there structural
differences between classical and N-terminal RASSFs [3], but they
also might be transcriptionally regulated in different ways.
5. Conclusion
As described in this review, the tumor suppressor function of
RASSF proteins are primarily determined by their ability to inhibit
2680 N. Volodko et al. / FEBS Letters 588 (2014) 2671–2684cell growth and proliferation and to promote cell death in addition
to other distinct functions. RASSF proteins exert their diverse func-
tions through interaction with various proteins and are regulated
through complex mechanisms, including promoter hypermethyla-
tion, histone modiﬁcations, protein post-translational modiﬁca-
tions, polymorphic changes resulting in functional differences
and miRNA regulation. Epigenetic silencing of RASSF genes via pro-
moter speciﬁc methylation is reported in many cancers and is be-
lieved to have a diagnostic and prognostic value. Recent data
suggest that inﬂammation may potentially serve as a trigger for
epigenetic silencing which may contribute to cancer development.
RASSF1A promoter hypermethylation was detected in inﬂamma-
tory bowel disease patients as well as in pancreatitis patients to
suggest that pre-cancer inﬂammatory states involve loss of RASSF1
function. It will be interesting to see if this holds true in other
inﬂammatory diseases such as arthritis and asthma. Despite of all
the progress made in recent years, cancer epigenetics still has
many unanswered questions and holds big potential for future re-
search in diagnostics and therapeutics. More research is needed to
provide a better understanding of how these changes arise and if
these changes can be developed into a diagnostic and/or prognostic
markers. The RASSF family of proteins has given substantial insight
into tumor suppression mechanisms and have been ﬁrmly demon-
strated to be an important gene family for the appearance and pro-
gression of cancer.
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